Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

The presence of certain high-risk cytogenetic abnormalities, such as translocations (4;14) and (14;16) and deletion (17p), are known to have a negative impact on survival in multiple myeloma (MM). The phase 3 study ASPIRE (N = 792) demonstrated that progression-free survival (PFS) was significantly...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Avet-Loiseau, Hervé, Fonseca, Rafael, Siegel, David, Dimopoulos, Meletios A., Špička, Ivan, Masszi, Tamás, Hájek, Roman, Rosiñol, Laura, Goranova-Marinova, Vesselina, Mihaylov, Georgi, Maisnar, Vladimír, Mateos, Maria-Victoria, Wang, Michael, Niesvizky, Ruben, Oriol, Albert, Jakubowiak, Andrzej, Minarik, Jiri, Palumbo, Antonio, Bensinger, William, Kukreti, Vishal, Ben-Yehuda, Dina, Stewart, A. Keith, Obreja, Mihaela, Moreau, Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2016
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5009511/
https://ncbi.nlm.nih.gov/pubmed/27439911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-03-707596
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados